Histone Modifiers in Cancer: Friends or Foes?

Idan Cohen(Max Planck Institute of Immunobiology and Epigenetics), Elżbieta Poręba(Adam Mickiewicz University in Poznań), Kinga Kamieniarz-Gdula(Max Planck Institute of Immunobiology and Epigenetics), Robert Schneider(Max Planck Institute of Immunobiology and Epigenetics)
Genes & Cancer
June 1, 2011
Cited by 168Open Access
Full Text

Abstract

Covalent modifications of histones can regulate all DNA-dependent processes. In the last few years, it has become more and more evident that histone modifications are key players in the regulation of chromatin states and dynamics as well as in gene expression. Therefore, histone modifications and the enzymatic machineries that set them are crucial regulators that can control cellular proliferation, differentiation, plasticity, and malignancy processes. This review discusses the biology and biochemistry of covalent histone posttranslational modifications (PTMs) and evaluates the dual role of their modifiers in cancer: as oncogenes that can initiate and amplify tumorigenesis or as tumor suppressors.


Related Papers

No related papers found

Powered by citation graph analysis